HEALTH● LOWSep 13 · Sep 13, 2026, 5:32 PM
Scholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophy
Seeking Alpha Tech · north america
Scholar Rock's stock increased by 12% following FDA approval of its drug, isembyld, for spinal muscular atrophy. This article reports on a significant pharmaceutical development and its immediate financial impact.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH39m agoPope doing physical therapy, good recovery of lung that was operated onANSA [en]HEALTH40m agoPope doing physical therapy, good recovery of the operated lungANSA [en]HEALTH1h agoWHO boosts preparedness for Ebola-related virus in 3 countriesVanguard NigeriaHEALTH2h agoNAFDAC records 213 raids, 474 new cases in eight monthsPremium Times